Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer

Journal of Nuclear Medicine

Volumn 53, Issue 12, 2012, Pages 1883-1891

  Cho, Steve Y ^a,b   Gage, Kenneth L ^a   Mease, Ronnie C ^a,b   Senthamizhchelvan, Srinivasan ^a   Holt, Daniel P ^a   Jeffrey Kwanisai, Akimosa ^a   Endres, Christopher J ^a   Dannals, Robert F ^a   Sgouros, George ^a   Lodge, Martin ^b   Eisenberger, Mario A ^b   Rodriguez, Ronald ^b,c   Carducci, Michael A ^c   Rojas, Camilo ^d   Slusher, Barbara S ^d   Kozikowski, Alan P ^e   Pomper, Martin G ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

18F; PET CT; Prostate cancer; Prostate specific membrane antigen; Urea

Indexed keywords

FLUORODEOXYGLUCOSE F 18; N [N [1,3 DICARBOXYPROPYL]CARBAMOYL] 4 FLUOROBENZYL CYSTEINE F 18; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER WALL; BONE METASTASIS; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG SYNTHESIS; DRUG UPTAKE; DRUG URINE LEVEL; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; METASTASIS POTENTIAL; MOLECULAR IMAGING; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIOACTIVITY; RADIODIAGNOSIS; TUMOR LOCALIZATION; URINARY EXCRETION; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; BIOLOGICAL TRANSPORT; CYSTEINE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; RADIOMETRY; TISSUE DISTRIBUTION;

EID: 84870340190     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.104661     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Walczak JR, Carducci MA. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc. 2007;82:243-249. (Pubitemid 46198485)
3. Beltran H, Beer TM, Carducci MA, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60:279-290.
4. Chang SS, Reuter VE, Heston WD, Gaudin PB. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology. 2001;57:801-805.
5. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48:326-334. (Pubitemid 26279634)
6. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701. (Pubitemid 46560805)
7. Wilkinson S, Chodak G. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy. J Urol. 2004;172:133-136. (Pubitemid 41615054)
8. Elsässer-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med. 2009;50:606-611.
9. Tagawa ST, Beltran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116:1075-1083.
10. Barinka C, Rovenska M, Mlcochova P, et al. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem. 2007;50:3267-3273. (Pubitemid 47065975)
11. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
12. Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG. GCPII imaging and cancer. Curr Med Chem. 2012;19:1346-1359.
13. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001;44:298-301. (Pubitemid 32113579)
14. Holt DP, Ravert HT, Mathews WB, Horti A, Mease R, Dannals RF. A semi-automated microwave chemistry system for complete radiosynthesis, purification, and formulation of F-18 radiotracers [abstract]. J Labelled Comp Radiopharm. 2011;54:S426.
15. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). National Cancer Institute. Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm. Accessed October 23, 2012.
16. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol. 2000;27:627-630.
17. International Commission on Radiation Units and Measurements. Tissue Substitutes in Radiation Dosimetry and Measurement. Bethesda, MD: International Commission on Radiation Units and Measurements; 1989.
18. Pichardo JC, Trindade AA, Brindle JM, Bolch WE. Method for estimating skeletal spongiosa volume and active marrow mass in the adult male and adult female. J Nucl Med. 2007;48:1880-1888. (Pubitemid 350099334)
19. Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values - a report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. International Commission on Radiological Protection; 2002. Available at: http://altmine.mie.uc.edu/nuclear/hplib/icrp/ icrp%2089.pdf. Accessed October 23, 2012.
20. 82Rb. J Nucl Med. 2010;51:1592-1599.
21. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294-310. (Pubitemid 36999340)
22. Stabin M. Fundamentals of Nuclear Medicine Dosimetry. New York, NY: Springer; 2008.
23. Cloutier RJ, Smith SA, Watson EE, Snyder WS, Warner GG. Dose to the fetus from radionuclides in the bladder. Health Phys. 1973;25:147-161.
24. Leggett RW. Basic anatomical and physiological data for use in radiological protection: the skeleton - a report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP. 1995;25:1-80.
25. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. AJR. 2009;192:1455-1470.
26. Hillier SM, Kern AM, Maresca KP, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011;52:1087-1093.
27. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108:9578-9582.
28. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210-3216. (Pubitemid 40627867)
29. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15:45-55.
30. 11C] choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011;17:3751-3759.
31. 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68-78.
32. 18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med. 2010;51:183-192.
33. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
34. 123I- MIP1095 [abstract]. J Nucl Med. 2009;50(suppl 2):522.
35. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006; 30:628-636.
36. Helyar V, Mohan HK, Barwick T, et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging. 2010;37:706-713.
37. 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
38. Rojas C, Frazier ST, Flanary J, Slusher BS. Kinetics and inhibition of glutamate carboxypeptidase II using a microplate assay. Anal Biochem. 2002;310:50-54. (Pubitemid 35387330)
39. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals: addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008;38:1-197.